NCT03413384View on ClinicalTrials.gov

To Assess the Efficacy and Safety of Ceftriaxone in Patients With Mild to Moderate Parkinson's Disease Dementia

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

February 15, 2019

Primary Completion Date

July 28, 2025

Study Completion Date

December 31, 2025

Conditions
Parkinson's Disease Dementia
Interventions
DRUG

Ceftriaxone

1 g ceftriaxone per day for Day 1, 3, and 5 per cycle on a 2 weekly cycle

OTHER

Placebo

Placebo per day for Day 1, 3, and 5 per cycle on a 2 weekly cycle

Trial Locations (6)

100

National Taiwan University Hospital, Taipei

402

Chung Shan Medical University Hospital, Taichung

404

China Medical University Hospital, Taichung

500

Changhua Christian Hospital, Changhua

11217

Taipei Veterans General Hospital, Taipei

83301

Kaohsiung Chang Gung Memorial Hospital, Kaohsiung City

Sponsors

Lead Sponsor

BrainX Corporation
All Listed Sponsors
collaborator

Virginia Contract Research Organization Co., Ltd.

OTHER

lead

BrainX Corporation

INDUSTRY